Clinical Trial Search

Primary: Number of Participants With First Occurrence of SARS-CoV-2 Reverse Transcription Polymerase Chain Reaction (RT-PCR)-Positive Symptomatic COVID-19 With Onset at Least 14…

Primary: Negative Polymerase Chain Reaction (PCR) — 2; 7 Participants

Primary: Percentage of Participants With Seroresponse to the Spike (S) Antigen of AZD1222 as Measured by Meso Scale Discovery (MSD) Serology Assay — 100.0; 0.0; 100.0; 0.0…

Primary: SARS-CoV-2 Infection — 4; 2 Participants

Primary: COVID-19 Prophylaxis — 30; 105 Participants

Primary: COVID-19-free Survival — 464; 468; 454 Participants

Primary: Number of Participants With Local and Systemic Solicited Treatment Emergent Adverse Events (TEAEs) in Primary Vaccination Cohort (PVC):- AZD2816 (4), Booster…

Primary: Percent of Healthcare Workers Testing Positive for COVID-19. — 0; 0 percentage of healthcare workers

Primary: The Proportion of Patients With Acute Respiratory Viral Infections, Including COVID-19, at the End of the Prophylactic Period — 3; 13 participants

Primary: Number of Participants With Symptomatic COVID-19 at 60 Days — 24; 19 Participants — p=0.52

Primary: E Genes — 28.50; 27.33; 30.28; 27.80 Cycle

Primary: Percentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline Nasopharyngeal (NP) Swabs and Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With…

Primary: Number of New COVID 19 Infections — 25; 21 Participants

Primary: Number of Participants With Sustained Clinical Recovery — 425; 475 Participants

Primary: Number of Participants With Solicited Local Adverse Events (AE) During 7 Days After Vaccination — 5; 9; 16; 19 Participants

Primary: New COVID-19 Group Home Incidence — 1.61; 1.40; 0.16; 0.09 New COVID-19 cases per 100 person-months — p=0.89

Primary: The Incidence of COVID-2019 Cases. — 259.95 COVID-2019 cases per 1000 person

Primary: Number of Infected Subjects — 0; 11 Participants — p=< 0.0001

Primary: Number of Participants Infected With COVID-19 or COVID-19 Like Illness During the Trial — 13; 32 Participants — p=0.0112

Primary: COVID-19 Contamination Rate. — 2; 5 Participants

Primary: Cohort A: Percentage of Participants Who Have a Symptomatic RT-qPCR Confirmed SARS-CoV-2 Infection (Broad-term) During the EAP — 7.8; 1.4 Percentage of Participants…

Primary: Evaluation of Acceptability of Intervention as Measured by Acceptability Questionnaire — 4.47 score on a scale

Primary: Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection — 45; 53 Participants

Primary: Number of Participants With Binary Response — 73; 130 Participants — p=<0.001

Primary: Recruitment Feasibility — 46 Participants

Primary: Number of Participants With Adverse Events of Special Interest (AESIs) From Study Vaccination Through the End of the Study — 1; 3; 2; 0 Participants

Primary: Facebook Movement Metric — -6.082; -5.320; -2.603; -1.823 Percent change relative to Feb 2020

Primary: Number of Participants With First Case of SARS-CoV-2 RT-PCR-positive Symptomatic Illness — 8; 17; 12; 34 Participants — p=<0.001

Primary: Percentage of Participants Who Developed Symptomatic RT-PCR or RAT Confirmed SARS-CoV-2 Infection Through Day 14: Among Participants With Negative RT-PCR at Baseline…

Primary: Severity of COVID-19: Evaluation of the Severity of COVID-19 as Measured by the Maximum Difference From the Baseline Value in the OSCI Within 28 Days From the Start of…